Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 14/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991053 | 0.89 | KMT2A (0.51) | MEN1KMT2ATDP1ACE | |
| SCHEMBL993837 | 0.85 | PRCP (0.46) | FKBP1AMEN1KMT2ATDP1PRCP | |
| SCHEMBL993838 | 0.85 | PRCP (0.46) | FKBP1AMEN1KMT2ATDP1PRCP | |
| SCHEMBL11980699 | 0.83 | FKBP1A (0.53) | FKBP1ATDP1ACEKLK7KLK5 | |
| SCHEMBL19442013 | 0.83 | FKBP1A (0.53) | FKBP1AACEKLK7KLK5 | |
| SCHEMBL9094520 | 0.80 | FKBP1A (0.58) | FKBP1APRCPACE | |
| SCHEMBL11556689 | 0.79 | TDP1 (0.67) | MEN1KMT2ATDP1 | |
| SCHEMBL9475212 | 0.79 | FKBP1A (0.59) | FKBP1APRCPACE | |
| SCHEMBL12950286 | 0.76 | PRCP (0.45) | FKBP1APRCPACE | |
| SCHEMBL10380778 | 0.76 | PRCP (0.62) | FKBP1APRCPKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2641906-B1 | Tofa analogs useful in treating dermatological disorders or conditions | DERMIRA CANADA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561557-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | The Regents of the University of California (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026012-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | LIPC, GPR119, PNLIP | FKBP1A 2522/4885MEN1 3713/4885KMT2A 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.